KPIs & Operating Metrics(New)
Additions To Property And EquipmentAdjusted Income Before TaxAdjusted Income Before Tax By SegmentAssets By SegmentBreakdown Of AssetsCardiovascular/Metabolism/Other RevenueCardiovascular/Metabolism/Other Revenue AnnualConsumer RevenueContractual BoligationsCost Of Products SoldDisaggregated Revenue Mix %Disaggregated RevenuesEarnings Before Taxes On IncomeEbt By SegmentEbt By Segment AnnualEbt Margin By Segment Annual %Employee StatisticsFacilites By RegionGross ProfitImmunology RevenueImmunology Revenue AnnualInfectious Diseases RevenueInfectious Diseases Revenue AnnualInnovative Medicine Revenue Breakdown AnnualInternational Sales By SegmentInterventional Solutions Revenue AnnualInventoriesLong Lived Assets By RegionMedical Devices RevenueMedical Devices Revenue AnnualMedtech Revenue Breakdown AnnualNeurosciences RevenueNeurosciences Revenue AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology RevenueOncology Revenue AnnualOPEX SegregationOrthopaedics Revenue AnnualPharmaceutical Revenue BreakdownProperty And Equipment SegregationPulmonary Hypertension RevenuePulmonary Hypertension Revenue AnnualRevenue By RegionRevenue By Region %Revenue By Region (Annual)Revenue By Region (Annual) %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Square Footage By RegionSurgery Revenue AnnualUs Sales By SegmentVision Revenue Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Johnson & Johnson (JNJ) Gross Profit (2016 - 2025)

Historic Gross Profit for Johnson & Johnson (JNJ) over the last 17 years, with Q3 2025 value amounting to $16.7 billion.

  • Johnson & Johnson's Gross Profit rose 762.19% to $16.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $62.7 billion, marking a year-over-year increase of 359.67%. This contributed to the annual value of $61.4 billion for FY2024, which is 468.21% up from last year.
  • Latest data reveals that Johnson & Johnson reported Gross Profit of $16.7 billion as of Q3 2025, which was up 762.19% from $16.1 billion recorded in Q2 2025.
  • Over the past 5 years, Johnson & Johnson's Gross Profit peaked at $16.7 billion during Q3 2025, and registered a low of $13.8 billion during Q2 2022.
  • For the 5-year period, Johnson & Johnson's Gross Profit averaged around $15.0 billion, with its median value being $14.9 billion (2024).
  • Per our database at Business Quant, Johnson & Johnson's Gross Profit surged by 3375.01% in 2021 and then tumbled by 1407.26% in 2022.
  • Over the past 5 years, Johnson & Johnson's Gross Profit (Quarter) stood at $16.1 billion in 2021, then decreased by 14.07% to $13.8 billion in 2022, then grew by 5.59% to $14.6 billion in 2023, then grew by 5.45% to $15.4 billion in 2024, then increased by 8.43% to $16.7 billion in 2025.
  • Its last three reported values are $16.7 billion in Q3 2025, $16.1 billion for Q2 2025, and $14.5 billion during Q1 2025.